BCL2L1 and Thrombocytopenia: Navitoclax treatment results in dose-dependent thrombocytopenia due to BCL-XL inhibition as well as T-cell lymphopenia, the latter of which is potentially related to the efficacy in the closely related NK cells found in this study50.